Phase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)

V.C. Dieras; M. Martin Jimenez; C.C.M. O'Sullivan; J. Sohn; K. Tryfonidis; L. Santarpia; S. Yang; E.P. Hamilton

doi:10.1016/j.annonc.2022.03.226

YUHSpace

BROWSE

0 150

Cited 0 times in

Phase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)

Authors: V.C. Dieras ; M. Martin Jimenez ; C.C.M. O'Sullivan ; J. Sohn ; K. Tryfonidis ; L. Santarpia ; S. Yang ; E.P. Hamilton

Citation: ANNALS OF ONCOLOGY, Vol.33(Supplement 3) : S222, 2022-05

Journal Title: ANNALS OF ONCOLOGY

ISSN: 0923-7534

Issue Date: 2022-05

Full Text: https://www.sciencedirect.com/science/article/pii/S0923753422006056

DOI: 10.1016/j.annonc.2022.03.226

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/194652

사서에게 알리기

Show full item record Find it @ YMLIB

License

YUHSpace: Phase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)

YUHSpace

BROWSE

Browse

Links